ANG Lifesciences India Limited

ANG6

INE236W01016

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 10:16:20 04/07/2024 am IST			5-day change	1st Jan Change
52.52 ^INR	-0.28%		+1.49%	-24.33%

13/06	ANG Lifesciences India Limited Announces Cessation of Pawanjit Singh as Independent Director	CI
30/05	ANG Lifesciences India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

ANG Lifesciences India Limited Resignation Mr. Sarvinder Singh, Independent Director

February 16, 2019 at 05:35 pm IST

ANG Lifesciences India Limited announced that Mr. Sarvinder Singh, Independent Director has resigned from the Board of the Company with effect Feb. 16, 2019.

Latest news about ANG Lifesciences India Limited

ANG Lifesciences India Limited Announces Cessation of Pawanjit Singh as Independent Director	13/06	CI
ANG Lifesciences India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
ANG Lifesciences India Limited Approves the Appointment of Saruchi Gupta as Chief Financial Officer	13/05	CI
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
ANG Lifesciences India CFO Steps Down	16/23/16	MT
ANG Lifesciences India Limited Announces Resignation of Neeraj Gupta as Chief Financial Officer	14/23/14	CI
ANG Lifesciences India Limited Appoints Rohit Mittal as Additional Director (Non-Executive Non Independent Director)	11/23/11	CI
ANG Lifesciences India Limited Informs Mrs. Sudesh Kumari Resigns as Non-Executive Non Independent Director	11/23/11	CI
ANG Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
ANG Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
ANG Lifesciences India Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
ANG Lifesciences India Limited Appoints Neeraj Gupta as the CFO	30/23/30	CI
ANG Lifesciences India Limited announced that it expects to receive INR 60.5 million in funding from ANG Capital Investments Private Limited	05/23/05	CI
ANG Lifesciences India Limited announced that it expects to receive INR 60.5 million in funding from ANG Capital Investments Private Limited	06/23/06	CI
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
ANG Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
ANG Lifesciences India CFO Resigns	06/22/06	MT
ANG Lifesciences India Limited Announces Resignation of Subodh Sharma as Chief Financial Officer	05/22/05	CI
ANG Lifesciences India Limited announced that it expects to receive INR 20 million in funding	29/22/29	CI
ANG Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/22/14	CI
Infomerics Valuation Raises Rating on ANG Lifesciences India's Long-term Bank Financing; Outlook Stable	06/22/06	MT
ANG Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	14/22/14	CI
ANG Lifesciences Gets BSE Nod for Bonus Issue of Shares	11/22/11	MT
ANG Lifesciences India Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/22/30	CI
ANG Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/22/30	CI

Chart ANG Lifesciences India Limited

Duration

Period

More charts

ANG Lifesciences India Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. It operates in two segments, namely pharmaceuticals and printing and packagings. The Company's products portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. It is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syru ps and Suspension, and Lotions, among others. The Company's subsidiaries include ANG Lifesciences India Limited and Mansa Prints and Publishers Limited.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANG LIFESCIENCES INDIA LIMITED	-24.33%	8.24M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+38.59%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+13.40%	238B
ROCHE HOLDING AG	+0.61%	221B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	166B